Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial Spotlight
Lymphoma
Phase 2 teclistamab BCMA×CD3 T‑cell–redirecting bispecific antibody in R/R Waldenström’s macroglobulinemia.
This single-group, open-label Phase 2 study evaluates teclistamab (a BCMA×CD3 bispecific monoclonal antibody that redirects T cells to kill BCMA-expressing malignant B-lineage cells) in relapsed or refractory…
NCT07791498 Exploratory - New trial
Kidney cancer
Phase 1 cabozantinib multi-kinase (MET/AXL/VEGFR2) inhibitor + nivolumab PD-1 mAb
MD Anderson’s Phase 1 proof-of-concept study tests whether cabozantinib plus nivolumab reshapes the *bone* immune microenvironment in clear cell renal cell carcinoma (ccRCC) with bone metastases, using paired…
NCT07187869 Exploratory - New trial Spotlight
Prostate cancer
Phase 1/2 ADI-212 PSMA-targeted γδ (Vδ1) CAR-T cells in mCRPC.
This Phase 1/2 multicenter, open-label, dose-escalation (3+3) and dose-expansion study evaluates ADI-212, an allogeneic engineered γδ (Vδ1) CAR-T cell therapy that targets PSMA on prostate cancer cells, sponsored by…
NCT07793435 First-in-human - New trial
Non-small cell lung cancer
Phase 2/3 AMT-116 CD44v9-targeted topoisomerase I ADC vs docetaxel±ramucirumab in NSCLC.
This open-label, global, multicenter, randomized Phase 2/3 study from Multitude Therapeutics tests AMT-116, a CD44v9-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to…
NCT07718737 Exploratory - New trial
Multiple myeloma
Phase 1 BCMA–dnTGFβRII armored CAR-T (BCMA CAR + TGF-β resistance)
This Phase 1, single-arm, open-label, dose-escalation/expansion study tests an “armored” BCMA-directed CAR T-cell product in adults with relapsed/refractory multiple myeloma after at least 4 prior lines, including…
NCT05976555 First-in-human - New trial
Acute lymphoblastic leukemia
Phase 1 BAFFR-CAR T (BAFF-R–targeted CAR-T) in relapsed/refractory B-ALL/B-LL
City of Hope is running a Phase 1, first-in-human study of autologous BAFFR-targeting CAR T cells, an adoptive cell therapy where a patient’s own T cells are genetically engineered to recognize BAFF-R…
NCT07758673 First-in-human - New trial
Liver and bile duct cancer
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer.
This multi-institutional Phase 2, open-label, single-arm study evaluates daraxonrasib monotherapy in patients with unresectable or advanced/metastatic biliary tract cancers (including cholangiocarcinoma, gallbladder…
NCT07793253 Exploratory - New trial
Ovarian cancer
Phase 2 sacituzumab tirumotecan (MK-2870) TROP2 ADC ± pembrolizumab PD-1 mAb in OCCC
This randomized Phase 2 study at Tufts Medical Center tests sacituzumab tirumotecan (MK-2870), a TROP2-directed antibody-drug conjugate that delivers a belotecan-derived topoisomerase I–inhibitor payload, either…
NCT07718854 Exploratory - New trial Spotlight
Colorectal cancer
Phase 3 petosemtamab (EGFR×LGR5 bispecific antibody) vs cetuximab in 1L left-sided mCRC
Genmab’s LiGeR-CRC1 is a randomized, open-label Phase 3 trial testing whether petosemtamab (MCLA-158; an EGFR×LGR5-directed bispecific monoclonal antibody designed to block EGFR signaling and target LGR5-expressing…
NCT07702032 Registrational - New trial
Colorectal cancer
Phase 2 cemiplimab PD-1 antibody trial adds fianlimab LAG-3 and REGN7075 EGFR×CD28 bispecific.
NSABP Foundation’s EMPIRE (NSABP FC-13) is an open-label, randomized Phase 2 platform study testing whether adjuvant immunotherapy can clear ctDNA-defined minimal residual disease (MRD) and reduce recurrence after…
NCT07058012 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 2 SIR2501 SARM1 inhibitor aims to prevent paclitaxel-induced peripheral neuropathy.
This Phase 2, open-label, sequential-cohort study evaluates SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy, with primary goals of characterizing safety, tolerability,…
NCT07765446 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Sutetinib (irreversible EGFR-TKI) drives 70.8% ORR and 13.7-mo PFS in 1L uncommon EGFR-mutant NSCLC
Sutetinib is an oral irreversible EGFR tyrosine kinase inhibitor (TKI) evaluated in a multicenter, open-label, single-arm Phase IIb trial in locally advanced/metastatic NSCLC with uncommon EGFR mutations (G719X,…
NCT05168566 - Trial result
Non-small cell lung cancer
Crizotinib (ALK TKI) Fails to Improve DFS as Adjuvant Therapy in Resected ALK+ NSCLC (E4512)
Crizotinib is a first-generation oral ALK tyrosine kinase inhibitor (TKI) evaluated as adjuvant therapy in the ECOG-ACRIN E4512 Phase 3 trial (NCT02201992) versus observation in resected early-stage ALK+ NSCLC (tumor…
NCT02201992 - Trial result
Non-small cell lung cancer
Ociperlimab (TIGIT) + tislelizumab (PD-1) with cCRT shows numerically longer PFS vs durvalumab in unresectable stage III NSCLC (AdvanTIG-301)
Ociperlimab is an anti-TIGIT antibody and tislelizumab is an anti–PD-1 antibody; AdvanTIG-301 (Phase III, open-label, randomized, multi-arm; NCT04866017) tested concurrent I/O with concurrent chemoradiotherapy (cCRT)…
NCT04866017 - Trial result
Breast cancer
Olaparib (PARP inhibitor) Sustains OS/IDFS Gains at 6.1 Years in gBRCA High-Risk HER2− eBC (OlympiA)
Olaparib (Lynparza), an oral PARP inhibitor that exploits homologous recombination deficiency in germline BRCA1/2–mutated tumors, was tested vs placebo for 1 year in the randomized Phase 3 OlympiA trial (NCT02032823)…
NCT02032823 - Trial result
Head and neck cancer
Imaging-detected extranodal extension (iENE) upstages HPV+ OPC but only modestly improves TNM9 risk separation
In this secondary analysis of the Phase III NRG/RTOG 1016 HPV-mediated (p16+) oropharyngeal cancer trial (NCT01302834), pretreatment CT simulation scans were reread by 2 expert head-and-neck radiologists to…
NCT01302834 - Trial result
Colorectal cancer
SCRT (5×5Gy) + CAPOX Total Neoadjuvant Therapy Improves 5-Year OS vs Long-Course Capecitabine-CRT in LARC (STELLAR)
Short-course radiotherapy (SCRT; 5Gy×5) followed by consolidation chemotherapy (CAPOX) as total neoadjuvant therapy (TNT) was compared with standard long-course chemoradiotherapy (LCRT ~50Gy with concurrent…
NCT02533271 - Trial result
Sarcoma and GIST
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients
Vimseltinib is an oral “switch-control” kinase inhibitor of CSF1R designed to blunt the CSF1-driven macrophage biology underlying tenosynovial giant cell tumor (TGCT). In the multicenter, open-label Phase 2 expansion…
NCT03069469 - Trial result Spotlight
Lymphoma
BV (CD30-directed ADC) + nivolumab (PD-1) + limited chemo delivers 97% 2-year PFS in nonbulky early-stage cHL (SGN35-027)
Brentuximab vedotin (BV) is a CD30-targeted antibody–drug conjugate and nivolumab is a PD-1 checkpoint inhibitor; in SGN35-027 Part C (Phase 2; NCT03646123), previously untreated Ann Arbor stage I–II nonbulky…
NCT03646123 - Trial result
Lymphoma
Epcoritamab (CD3×CD20) + R² Drives 95% ORR in Frontline Follicular Lymphoma—But Infection Risk Looms
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody, here added to the chemotherapy-free backbone of rituximab + lenalidomide (R²) as first-line therapy. In the open-label, multicentre EPCORE…
NCT04663347 - Trial result
Liver and bile duct cancer
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC
STRIDE is dual-checkpoint immunotherapy (anti–PD-L1 durvalumab + single priming dose anti–CTLA-4 tremelimumab); lenvatinib is an oral multikinase inhibitor (VEGFR/FGFR/PDGFR/RET/KIT). In the global Phase 3 EMERALD-3…
NCT05301842 - Trial result
Ovarian cancer
Darolutamide (androgen receptor inhibitor) + leuprolide + exemestane shows low ORR but 8.5-mo mPFS in AI-refractory recurrent AGCT
Darolutamide is an oral androgen receptor (AR) antagonist combined here with ovarian suppression (leuprolide acetate) plus steroidal aromatase inhibition (exemestane) in a single-arm Phase II cooperative group study…
NCT06169124 - New trial Spotlight
Non-small cell lung cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D-selective RAS(ON) inhibitor + pembrolizumab chemo in NSCLC
Revolution Medicines is running RASolve 308, a randomized, double-blind, placebo-controlled Phase 3 trial testing whether adding zoldonrasib (RMC-9805)—a KRAS G12D-selective, active-state “RAS(ON)” small-molecule…
NCT07777822 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 3 divarasib KRAS G12C inhibitor vs PD-1 immunotherapy/observation after resection.
Hoffmann‑La Roche’s KRASCENDO 3 (Phase 3, randomized, open-label) tests whether divarasib—an oral, covalent KRAS G12C small‑molecule inhibitor—improves outcomes versus investigator’s choice of pembrolizumab (Merck)…
NCT07541170 Registrational - New trial
Non-small cell lung cancer
Phase 1b NXP900 SRC family kinase inhibitor plus lorlatinib ALK/ROS1 inhibitor in ALK+ NSCLC.
This multi-center, open-label Phase 1b trial from Nuvectis Pharma tests escalating oral doses of NXP900 (a small-molecule SRC family kinase inhibitor) combined with lorlatinib (a small-molecule ALK and ROS1 tyrosine…
NCT07784959 Exploratory - New trial
Multiple myeloma
Phase 1b JNJ-79635322 BCMA×GPRC5D×CD3 T‑cell–redirecting trispecific antibody combos in multiple myeloma
This Janssen Research & Development (Johnson & Johnson) Phase 1b, open-label, multi-part dose-escalation/expansion study is designed to define recommended Phase 2 dose(s) and schedules for JNJ-79635322 (a…
NCT06768489 Exploratory - New trial
Multiple myeloma
Phase 2 ramantamig BCMA×GPRC5D×CD3 trispecific mAb with IL-6R blockade (tocilizumab)
Janssen Research & Development (Johnson & Johnson) is running this Phase 2 randomized, double-blind, placebo-controlled trial to test whether a single prophylactic dose of tocilizumab—an IL-6 receptor–blocking…
NCT07589634 Exploratory - New trial
Multiple myeloma
Phase 2 elranatamab BCMA×CD3 bispecific with IL-6R blockade to prevent CRS
SCRI Development Innovations (part of Sarah Cannon Research Institute/SCRI Oncology Partners) is running this Phase 2, open-label, nonrandomized, single-arm CORE-MM study to test whether outpatient elranatamab…
NCT07637578 Exploratory - New trial
Multiple myeloma
Phase 3 etentamig (ABBV-383) BCMA×CD3 bispecific T‑cell engager plus pomalidomide in 2L+ RRMM.
AbbVie’s Phase 3, multicenter, randomized, open-label study tests whether adding etentamig—an anti-BCMA×anti-CD3 bispecific antibody that redirects T cells to kill BCMA-expressing myeloma cells—improves outcomes when…
NCT07728188 Registrational - New trial
Multiple myeloma
Phase 1 Orca-Q naïve T-cell–depleted allogeneic HSCT to reduce GVHD in high-risk myeloma
This Phase 1 interventional study at UC Davis evaluates ORCA-Q allogeneic hematopoietic stem cell transplantation as a potentially safer, immune-engineered way to deliver graft-versus-myeloma activity in…
NCT07759102 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.